The Alliance for Regenerative Medicine Releases Agenda for 2017 Cell & Gene Meeting on the Mesa - Seite 2

Slate of presenting companies:
4D Molecular Therapeutics; Abeona Therapeutics; Acucela; Adaptimmune; AGTC; American Gene Technologies; Asterias Biotherapeutics; Athersys; Audentes Therapeutics; AVROBIO; Bellicum Pharmaceuticals; Benitec Biopharma; Biostage; BioTime; bluebird bio; BlueRock Therapeutics; B-MoGen Biotechnologies; Bone Therapeutics; Caladrius Biosciences; Capricor Therapeutics; Cell Medica; CellSeed; Cellular Dynamics International; Cesca Therapeutics; CRISPR Therapeutics; Cynata Therapeutics; DiscGenics; Fate Therapeutics; Fibrocell; GammaDelta Therapeutics; Healios; Histogenics; Homology Medicines; Intellia Therapeutics; jCyte; Juventas Therapeutics; Lysogene; MaxCyte; Medeor Therapeutics; MEDIPOST America; Mesoblast; MiMedx; MolMed; Orbsen Therapeutics; Orchard Therapeutics; Oxford BioMedica; PDC*line; Precision Biosciences; Promethera Biosciences; REGENXBIO; ReNeuron; Renova Therapeutics; RoosterBio; Sangamo Therapeutics; SCM Lifescience; Semma Therapeutics; Sentien Biotechnologies; Sigilon Therapeutics; StemBioSys; Synpromics; Terumo BCT; TiGenix; TxCell; Universal Cells; Vericel; ViaCyte; Vivet Therapeutics; WindMIL Therapeutics.

Following the close of the Partnering Forum on October 5, there will be a Public Forum presentation and reception held at the Sanford Consortium for Regenerative Medicine. Donna Skerrett, M.D., chief medical officer of Mesoblast, will introduce keynote speaker and Nobel Laureate Thomas Südhof, M.D., Professor of Molecular and Cellular Physiology; Neurology and Neurological Sciences; and Psychiatry and Behavioral Science at Stanford University; and Investigator at the Howard Hughes Medical Institute. Dr. Südhof's presentation is titled, "Towards a Better Understanding of Neuropsychiatric Disorders: The Role of Synapses."

The Scientific Symposium, held October 6 at the Salk Institute for Biological Studies, will feature numerous talks, panels and discussions led by prominent international scientists and more than 35 posters featuring the latest scientific discoveries in the world of regenerative medicine and advanced therapies. The discussions will cover scientific advances related to immuno-oncology; progenitors and stem cells; the use of tissue organoids in several biological applications; stem cells and cancer and more.

For full details on the agenda and further information about the event, please visit www.meetingonthemesa.com.

Registration is complimentary for investors and credentialed members of the media. For members of the media interested in attending, please contact Lyndsey Scull at [e-mail].

About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 270 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.

The Alliance for Regenerative Medicine
Lyndsey Scull
202 213 7086
[e-mail]